Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Wednesday, Jul 19, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x